Beijing SL Pharmaceutical Co Ltd
Beijing SL Pharmaceutical Co., Ltd., a biopharmaceutical company, research, development, and production of genetic engineering and related drugs People's Republic of China and internationally. The company's finished formulations include temozolomide; arsenic trioxide; lenalidomide capsules; pegylated human granulocyte-stimulating factor injection; human granulocyte-cell stimulating factor injecti… Read more
Market Cap & Net Worth: Beijing SL Pharmaceutical Co Ltd (002038)
Beijing SL Pharmaceutical Co Ltd (SHE:002038) has a market capitalization of $856.91 Million (CN¥6.29 Billion) as of March 19, 2026. Listed on the SHE stock exchange, this China-based company holds position #10046 globally and #2158 in its home market, demonstrating a -1.29% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Beijing SL Pharmaceutical Co Ltd's stock price CN¥6.12 by its total outstanding shares 1027350000 (1.03 Billion).
Beijing SL Pharmaceutical Co Ltd Market Cap History: 2015 to 2026
Beijing SL Pharmaceutical Co Ltd's market capitalization history from 2015 to 2026. Data shows change from $2.82 Billion to $856.91 Million (-9.51% CAGR).
Beijing SL Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Beijing SL Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.58x
Beijing SL Pharmaceutical Co Ltd's market cap is 1.58 times its annual revenue
1.02x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $2.82 Billion | $1.16 Billion | $575.05 Million | 2.44x | 4.90x |
| 2016 | $2.26 Billion | $1.01 Billion | $452.11 Million | 2.24x | 5.00x |
| 2017 | $2.64 Billion | $1.24 Billion | $533.58 Million | 2.13x | 4.95x |
| 2018 | $2.14 Billion | $2.17 Billion | $571.45 Million | 0.99x | 3.75x |
| 2019 | $1.72 Billion | $2.03 Billion | $486.78 Million | 0.85x | 3.54x |
| 2020 | $1.34 Billion | $1.11 Billion | $364.71 Million | 1.21x | 3.69x |
| 2021 | $1.45 Billion | $1.21 Billion | $425.94 Million | 1.20x | 3.41x |
| 2022 | $1.12 Billion | $1.05 Billion | $234.40 Million | 1.06x | 4.76x |
| 2023 | $1.40 Billion | $1.02 Billion | $416.69 Million | 1.37x | 3.35x |
| 2024 | $1.05 Billion | $660.42 Million | -$74.07 Million | 1.58x | N/A |
Competitor Companies of 002038 by Market Capitalization
Companies near Beijing SL Pharmaceutical Co Ltd in the global market cap rankings as of March 19, 2026.
Key companies related to Beijing SL Pharmaceutical Co Ltd by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Beijing SL Pharmaceutical Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Beijing SL Pharmaceutical Co Ltd's market cap moved from $2.82 Billion to $ 856.91 Million, with a yearly change of -9.51%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥856.91 Million | -16.96% |
| 2025 | CN¥1.03 Billion | -1.34% |
| 2024 | CN¥1.05 Billion | -25.17% |
| 2023 | CN¥1.40 Billion | +25.23% |
| 2022 | CN¥1.12 Billion | -23.19% |
| 2021 | CN¥1.45 Billion | +8.10% |
| 2020 | CN¥1.34 Billion | -22.01% |
| 2019 | CN¥1.72 Billion | -19.49% |
| 2018 | CN¥2.14 Billion | -18.96% |
| 2017 | CN¥2.64 Billion | +16.76% |
| 2016 | CN¥2.26 Billion | -19.77% |
| 2015 | CN¥2.82 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Beijing SL Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $856.91 Million USD |
| MoneyControl | $856.91 Million USD |
| MarketWatch | $856.91 Million USD |
| marketcap.company | $856.91 Million USD |
| Reuters | $856.91 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.